Characterisation of the Biochemical Profile and Physiology of the Coronary Circulation in Takotsubo Syndrome
Trial Parameters
Brief Summary
Consecutive consenting patients over the age of 18 years diagnosed with Takotsubo syndrome according to the position statement of the European Journal of Heart Failure (2016) will be included in the study. The primary endpoint is to evaluate the incidence of coronary microcirculation dysfunction and its correlation with the clinical presentation and the prognosis in patients with TAKO-Tsubo syndrome. Secondary endpoints will be to assess the incidence of in-hospital mortality, the prevalence of cardiogenic shock, the correlation between the levels of biomarkers analyzed, microvascular dysfunction, perceived quality of life, and angina severity during hospitalization and at subsequent follow-ups, and the influence of knowledge of the level of microvascular dysfunction on clinical management and prescribed therapies. Enrolment: 2 years, follow-up: 1 month and 1 year. Total: 3 years.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Diagnosis of Takotsubo syndrome * Signing of informed consent Exclusion Criteria: * Age \<18 years; * Refusal to sign written informed consent.